Revenue
No reported data
Bicara Therapeutics Inc. (BCAX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | — | $63.6M | $30.6M |
| Operating expenses | $155.6M | $82.4M | $39.9M |
| Operating income | −$155.6M | −$82.4M | −$39.9M |
| Net income | −$137.9M | −$68.0M | −$52.0M |
| Basic EPSper diluted share | -$2.52 | -$4.05 | -$89.61 |
| Diluted EPSper diluted share | -$2.52 | -$4.05 | -$89.61 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2026Form 4 · 10b5-1 | Hyep IvanChief Financial Officer | SellCommon Stock | 9.2K | $20.42 | $187.9K | 145.4K |
| May 18, 2026Form 4 · 10b5-1 | Mazumdar ClaireChief Executive Officer | SellCommon Stock | 3.0K | $20.35 | $60.6K | 362.2K |
| May 18, 2026Form 4 · 10b5-1 | Mazumdar ClaireChief Executive Officer | SellCommon Stock | 12.0K | $19.96 | $240.0K | 365.1K |
| May 15, 2026Form 4 · 10b5-1 | Cohlhepp RyanPresident and COO | SellCommon Stock | 4.5K | $20.29 | $91.3K | 191.6K |
| May 15, 2026Form 4 · 10b5-1 | Cohlhepp RyanPresident and COO | SellCommon Stock | 8.0K | $20.29 | $162.3K | 196.1K |